BOSTON--(

波士顿--(

BUSINESS WIRE

商业热线

)--

)--

Atalanta Therapeutics

亚特兰大治疗学

, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 million Series B financing to support Phase 1 clinical trials of the company’s investigational RNAi therapies for KCNT1-related epilepsy and Huntington’s disease.

，一家开创RNA干扰（RNAi）治疗神经系统疾病的生物技术公司，今天宣布完成9700万美元的B系列融资，以支持该公司针对KCNT1相关癫痫和亨廷顿舞蹈病的研究性RNAi疗法的第一阶段临床试验。

The financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from other new investors RiverVest Venture Partners, funds managed by abrdn Inc, Novartis Venture Fund, Pictet Alternative Advisors, Mirae Asset Financial Group, and GHR Foundation alongside existing investor F-Prime Capital..

此次融资由EQT Life Sciences和赛诺菲风险投资公司共同牵头，其他新投资者RiverVest Venture Partners、abrdn Inc管理的基金、诺华风险基金、Pictet Alternative Advisors、Mirae Asset Financial Group和GHR Foundation以及现有投资者F-Prime Capital共同参与。。

“

“

This financing validates the truly transformative potential of Atalanta’s best-in-class di-siRNA platform for delivering oligonucleotide therapies to the central nervous system and the exciting promise of our expansive wholly-owned pipeline,” said Alicia Secor, Atalanta’s president and chief executive officer.

亚特兰大总裁兼首席执行官艾丽西亚·塞科（AliciaSecor）表示：“这笔资金验证了亚特兰大一流的di-siRNA平台为中枢神经系统提供寡核苷酸治疗的真正变革潜力，以及我们庞大的全资管道的令人兴奋的前景。”。

“.

“.

Importantly, this Series B will support a path to the clinic for two programs for serious neurological diseases that today lack disease-modifying therapies — KCNT1-related epilepsy and Huntington’s disease — and will anchor our growing franchise of investigational medicines for Huntington’s disease.

重要的是，这一系列B将为目前缺乏疾病缓解疗法的严重神经系统疾病（KCNT1相关癫痫和亨廷顿舞蹈病）的两个项目提供通往诊所的途径，并将为我们越来越多的亨廷顿舞蹈病研究药物奠定基础。

We are diligently progressing these programs toward IND submissions this year so that we can start our Phase 1 trials and reach patients who are waiting.”.

我们正在努力推动这些计划在今年提交IND，以便我们可以开始我们的第一阶段试验，并惠及正在等待的患者。”。

In conjunction with this financing, the company announced the appointments of Arno de Wilde, M.D., Ph.D., MBA, managing director at EQT Life Sciences; Jason Hafler, Ph.D., managing director of Sanofi Ventures; and Niall O’Donnell, Ph.D., managing director of RiverVest Venture Partners to its Board of Directors..

结合此次融资，该公司宣布任命阿诺·德王尔德（Arno de Wilde），医学博士，MBA，EQT生命科学公司董事总经理；杰森·哈夫勒博士，赛诺菲风险投资公司董事总经理；以及RiverVest Venture Partners董事总经理Niall O'Donnell博士加入董事会。。

“

“

Atalanta’s di-siRNA technology has shown promising ability to durably silence disease-promoting genes throughout previously inaccessible regions of the brain and spinal cord — opening a wide range of treatment possibilities for devastating neurological diseases,” said Dr. de Wilde. “

亚特兰大的di-siRNA技术显示出在大脑和脊髓以前无法进入的区域持久沉默疾病促进基因的能力，为毁灭性神经疾病的治疗开辟了广泛的可能性，”de Wilde博士说。“”

EQT Life Sciences is proud to co-lead this investment in Atalanta’s future as part of such a high-quality investor syndicate, and we look forward to partnering with Atalanta’s leadership to support their continued success.”

EQT Life Sciences很自豪能够作为这样一个高质量投资者财团的一部分，共同领导这项对亚特兰大未来的投资，我们期待着与亚特兰大的领导层合作，支持他们继续取得成功。”

“

“

We are excited to partner with Atalanta as they enter their next chapter as a clinical-stage company,” said Dr. Hafler. “

哈夫勒博士说：“我们很高兴与亚特兰大合作，因为他们将进入临床阶段公司的下一个篇章。”。“”

Their success to-date is a strong validation of their ability to create meaningful new RNAi therapies, and Sanofi Ventures is glad to support Atalanta as they advance their pipeline.”

迄今为止，他们的成功有力地证明了他们创造有意义的新RNAi疗法的能力，赛诺菲风险投资公司很高兴在亚特兰大推进其管道的过程中支持他们。”

ATL-201 is Atalanta’s investigational therapy for KCNT1-related epilepsy, an early-onset seizure disorder and encephalopathy driven by gain-of-function variants in the

ATL-201是亚特兰大针对KCNT1相关癫痫的研究性治疗，这是一种早发性癫痫和脑病，由功能获得性变异驱动

KCNT1

KCNT1

gene. Infants and children with KCNT1-related epilepsy have severe, frequent seizures that are unable to be controlled with anti-seizure medications, and they often experience developmental delays and intellectual disability. ATL-201 is designed to reduce KCNT1 levels and to normalize neuronal excitability.

基因。患有KCNT1相关性癫痫的婴儿和儿童患有严重，频繁的癫痫发作，无法用抗癫痫药物控制，并且经常会出现发育迟缓和智力障碍。ATL-201旨在降低KCNT1水平并使神经元兴奋性正常化。

Preclinical studies have shown that ATL-201 produces a significant reduction of seizures and improvement in behavior with impressive durability and tolerability..

临床前研究表明，ATL-201可以显着减少癫痫发作并改善行为，具有令人印象深刻的耐久性和耐受性。。

The company’s second development candidate, ATL-101, is a di-siRNA designed to silence the

该公司的第二个开发候选者ATL-101是一种di-siRNA，旨在沉默

HTT

HTT公司

gene for the treatment of Huntington’s disease. Huntington’s disease is a progressive neurodegenerative disease caused by an expansion of the

用于治疗亨廷顿舞蹈病的基因。亨廷顿舞蹈病是一种进行性神经退行性疾病，由

HTT

HTT公司

gene, which leads to deterioration in a person’s physical, cognitive, and psychiatric abilities. Preclinical studies have shown that a single dose of ATL-101 produces a potent and strong reduction in

基因，导致一个人的身体、认知和精神能力下降。临床前研究表明，单剂量的ATL-101可以有效且强烈地降低

HTT

HTT公司

expression, including in deep brain regions, with six months of durability and excellent tolerability.

表达，包括在大脑深部区域，具有六个月的耐久性和出色的耐受性。

A full overview of the company’s pipeline, disclosed today, is available

今天披露的该公司管道的完整概述可供查阅

here

在这里

.

.

About Atalanta Therapeutics

关于亚特兰大治疗

Atalanta Therapeutics is a biotechnology company developing treatments for intractable diseases of the central nervous system using RNA interference. Atalanta’s unique platform of divalent small interfering RNA (di-siRNA) enables durable, selective gene silencing throughout the brain and spinal cord.

Atalanta Therapeutics是一家生物技术公司，利用RNA干扰技术开发中枢神经系统难治性疾病的治疗方法。亚特兰大独特的二价小干扰RNA（di-siRNA）平台可以在整个大脑和脊髓中实现持久的选择性基因沉默。

Atalanta is advancing a wholly owned pipeline of disease-modifying programs for Huntington’s disease, genetic epilepsy, severe chronic pain, and other neurological diseases in addition to partnered programs as part of a strategic collaboration with Genentech. Atalanta is headquartered in Boston, Mass.

作为与基因泰克战略合作的一部分，亚特兰大正在推进针对亨廷顿舞蹈病、遗传性癫痫、严重慢性疼痛和其他神经系统疾病的全资疾病缓解计划。亚特兰大总部位于马萨诸塞州波士顿。

For more information, visit .

有关更多信息，请访问。

www.atalantatx.com

www.atalanatx.com

.

.